Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus and increases the production of insulin, and reduces glucagon secretion, delaying gastric emptying. These separate, but related mechanisms of action of an amylin-analog and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction. Given the heterogeneity and complex pathogenesis of obesity, combination therapy with multiple pathophysiological targets is a logical approach to increasing weight loss response with pharmacotherapy. Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most common side effects of cagrilintide are gastrointestinal—mild-to-moderate nausea, vomiting, and constipation—which are generally transient and can be managed through gradual dose escalation and adequate hydration [74].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [74]
In the citing paper
“Parallel efforts with long-acting amylin analogues, exemplified by cagrilintide, are exploring combined regimens to modulate both homeostatic and hedonic feeding circuits more robustly than single-pathway agents [74].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [74]
Citations
Cites
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Mechanisms, Pathophysiology, and Management of Obesity
Heymsfield, S. B., & Wadden, T. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1514009 · Cited by 1,867
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Boutari, C., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155217 · Cited by 1,068
(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Gadde (2018) · doi:10.1016/j.jacc.2017.11.011 · Cited by 626
Physiological adaptations to weight loss and factors favouring weight regain
Greenway, F. L. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.59 · Cited by 431 · cited 2×
“13 Some of these physiological adaptations can favor weight regain by increasing hunger and promoting energy storage.”
BackgroundAssociation of body mass index with health care expenditures in the united states by age and sex
Ward, Z. J., Bleich, S. N., Long, M. W., & Gortmaker, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0247307 · Cited by 428
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278
Cited by
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 40
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“Parallel efforts with long-acting amylin analogues, exemplified by cagrilintide, are exploring combined regimens to modulate both homeostatic and hedonic feeding circuits more robustly than single-pathway agents [74].”
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Valladolid‐Acebes, I. (2024) · Biomedicines · doi:10.3390/biomedicines12112422 · Cited by 31
Metadata
- Authors
- D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H.
- Affiliations
- New York Medical College (US)
- Westchester Medical Center (US)
- Corresponding author
- D’Ascanio, Antonella M.
- Venue
- Cardiology in Review
- Published
- 2023-10-20
- Volume
- 32
- Issue
- 1
- Pages
- 83-90
- ISSN
- 1061-5377 (ISSN-L)
- OpenAlex
- W4323533074
- Cited by
- 46
- References
- 22
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 6 · 2023: 3
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiology in Review (publishedVersion)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- cagrilintide, amylin analogues, obesity treatment, semaglutide, GLP-1 receptor agonists, combination therapy, weight loss, appetite suppression, satiety, glucagon, glucagon-like peptide-1, pancreatic beta cells, pharmacotherapy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Obesity, Weight Loss, Glucagon-Like Peptide 1, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. https://app.cochat.ai/papers/10.1097/crd.0000000000000513
- The paper
- D’Ascanio, A. M., Mullally, J. A., & Frishman, W. H. (2024). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in Review. https://doi.org/10.1097/crd.0000000000000513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.